Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on September 24, 2020, primarily to announce the restatement of an amendment to its Share Purchase Agreement with Amgen Inc. This restated amendment, titled the 'Restated Second Amendment,' modifies an existing agreement under which Amgen initially purchased a significant stake in the company. The key change is the introduction of a 'Direct Purchase Option' that allows Amgen to buy additional shares to maintain its ownership at approximately 20.6% of BeiGene's outstanding share capital. This option is designed to offset dilution resulting from the company's equity incentive plans. It will be exercisable monthly, subject to Amgen's ownership falling below 20.4% and annual approval by BeiGene's independent shareholders. The company has secured a waiver from the Hong Kong Stock Exchange (HKEx) to facilitate this option, though shareholder approval is still required. The exercise period for this option has a defined term, potentially ending three years from its commencement or under specific conditions. The shares issued under this option will be in a private placement, exempt from registration requirements. For investors, this filing signals a continued strategic relationship with a major pharmaceutical player, Amgen, and a mechanism to prevent dilution of Amgen's significant stake. While this can be seen as a vote of confidence, it also means Amgen has a built-in ability to increase its ownership, which could impact future shareholder dynamics and dilution for other investors if not managed carefully. The need for shareholder approval at an upcoming EGM is a crucial upcoming event for investors to monitor.
Key Highlights
- 1BeOne Medicines Ltd. has entered into a Restated Second Amendment to its Share Purchase Agreement with Amgen Inc.
- 2The amendment grants Amgen a 'Direct Purchase Option' to acquire additional ordinary shares (in ADS form) to maintain its ownership at approximately 20.6% of the Company's outstanding share capital.
- 3The Direct Purchase Option is intended to counteract dilution resulting from the Company's equity incentive plans.
- 4Amgen can exercise the option monthly if its ownership falls below 20.4%, subject to annual approval by BeiGene's independent shareholders.
- 5The Hong Kong Stock Exchange (HKEx) has granted a waiver concerning the Direct Purchase Option, but the transaction still requires majority shareholder approval (excluding Amgen).
- 6The option exercise period will commence after shareholder approval and has a maximum term of three years.
- 7Shares issued under the option will be via private placement, exempt from registration under the Securities Act.